These data provide evidence that the single-agent PAPRi sensitivity observed in cell-based assay translates into substantive single-agent preclinical anti-tumour activity, yielding reduced disease progression and extended survival in mice carrying human RB1-defective osteosarcoma xenografts and selective sensitivity in patient-near models. Here, RB1 is linked to neoplasm.